vs

Side-by-side financial comparison of Agilent Technologies (A) and PACS Group, Inc. (PACS). Click either name above to swap in a different company.

Agilent Technologies is the larger business by last-quarter revenue ($1.8B vs $1.4B, roughly 1.3× PACS Group, Inc.). Agilent Technologies runs the higher net margin — 17.0% vs 4.4%, a 12.6% gap on every dollar of revenue. On growth, PACS Group, Inc. posted the faster year-over-year revenue change (18.4% vs 7.0%). Over the past eight quarters, PACS Group, Inc.'s revenue compounded faster (20.5% CAGR vs 6.9%).

Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emissi...

A vs PACS — Head-to-Head

Bigger by revenue
A
A
1.3× larger
A
$1.8B
$1.4B
PACS
Growing faster (revenue YoY)
PACS
PACS
+11.4% gap
PACS
18.4%
7.0%
A
Higher net margin
A
A
12.6% more per $
A
17.0%
4.4%
PACS
Faster 2-yr revenue CAGR
PACS
PACS
Annualised
PACS
20.5%
6.9%
A

Income Statement — Q1 2026 vs Q4 2025

Metric
A
A
PACS
PACS
Revenue
$1.8B
$1.4B
Net Profit
$305.0M
$59.7M
Gross Margin
52.6%
Operating Margin
19.6%
7.0%
Net Margin
17.0%
4.4%
Revenue YoY
7.0%
18.4%
Net Profit YoY
-4.1%
3022.5%
EPS (diluted)
$1.07
$0.42

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
A
A
PACS
PACS
Q1 26
$1.8B
Q4 25
$1.9B
$1.4B
Q3 25
$1.7B
$1.3B
Q2 25
$1.7B
$1.3B
Q1 25
$1.7B
$1.3B
Q4 24
$1.7B
$1.1B
Q3 24
$1.6B
$1.0B
Q2 24
$1.6B
$981.4M
Net Profit
A
A
PACS
PACS
Q1 26
$305.0M
Q4 25
$434.0M
$59.7M
Q3 25
$336.0M
$52.4M
Q2 25
$215.0M
$51.0M
Q1 25
$318.0M
$28.5M
Q4 24
$351.0M
$1.9M
Q3 24
$282.0M
$15.6M
Q2 24
$308.0M
$-10.9M
Gross Margin
A
A
PACS
PACS
Q1 26
52.6%
Q4 25
53.2%
Q3 25
51.1%
Q2 25
51.9%
Q1 25
53.5%
Q4 24
53.9%
Q3 24
54.2%
17.1%
Q2 24
54.4%
22.3%
Operating Margin
A
A
PACS
PACS
Q1 26
19.6%
Q4 25
23.8%
7.0%
Q3 25
20.7%
6.4%
Q2 25
18.0%
6.2%
Q1 25
22.4%
3.8%
Q4 24
24.0%
1.7%
Q3 24
21.1%
2.2%
Q2 24
23.1%
0.1%
Net Margin
A
A
PACS
PACS
Q1 26
17.0%
Q4 25
23.3%
4.4%
Q3 25
19.3%
3.9%
Q2 25
12.9%
3.9%
Q1 25
18.9%
2.2%
Q4 24
20.6%
0.2%
Q3 24
17.9%
1.5%
Q2 24
19.6%
-1.1%
EPS (diluted)
A
A
PACS
PACS
Q1 26
$1.07
Q4 25
$1.53
$0.42
Q3 25
$1.18
$0.32
Q2 25
$0.75
$0.31
Q1 25
$1.11
$0.17
Q4 24
$1.23
$-0.03
Q3 24
$0.97
$0.10
Q2 24
$1.05
$-0.07

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
A
A
PACS
PACS
Cash + ST InvestmentsLiquidity on hand
$1.8B
$197.0M
Total DebtLower is stronger
$3.0B
$353.2M
Stockholders' EquityBook value
$6.9B
$946.8M
Total Assets
$12.8B
$5.6B
Debt / EquityLower = less leverage
0.44×
0.37×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
A
A
PACS
PACS
Q1 26
$1.8B
Q4 25
$1.8B
$197.0M
Q3 25
$1.5B
$355.7M
Q2 25
$1.5B
$294.2M
Q1 25
$1.5B
$287.5M
Q4 24
$1.3B
$157.7M
Q3 24
$1.8B
$49.5M
Q2 24
$1.7B
$73.4M
Total Debt
A
A
PACS
PACS
Q1 26
$3.0B
Q4 25
$3.0B
$353.2M
Q3 25
$3.4B
Q2 25
$3.3B
Q1 25
$3.3B
Q4 24
$3.3B
$411.9M
Q3 24
$2.1B
Q2 24
$2.1B
Stockholders' Equity
A
A
PACS
PACS
Q1 26
$6.9B
Q4 25
$6.7B
$946.8M
Q3 25
$6.4B
$871.3M
Q2 25
$6.1B
$806.8M
Q1 25
$6.0B
$750.2M
Q4 24
$5.9B
$709.6M
Q3 24
$5.9B
$660.0M
Q2 24
$6.2B
$572.1M
Total Assets
A
A
PACS
PACS
Q1 26
$12.8B
Q4 25
$12.7B
$5.6B
Q3 25
$12.2B
$5.6B
Q2 25
$12.2B
$5.5B
Q1 25
$11.9B
$5.5B
Q4 24
$11.8B
$5.2B
Q3 24
$11.0B
$4.5B
Q2 24
$10.9B
$3.9B
Debt / Equity
A
A
PACS
PACS
Q1 26
0.44×
Q4 25
0.45×
0.37×
Q3 25
0.53×
Q2 25
0.55×
Q1 25
0.56×
Q4 24
0.57×
0.58×
Q3 24
0.36×
Q2 24
0.34×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
A
A
PACS
PACS
Operating Cash FlowLast quarter
$268.0M
$-3.4M
Free Cash FlowOCF − Capex
$175.0M
FCF MarginFCF / Revenue
9.7%
Capex IntensityCapex / Revenue
5.2%
Cash ConversionOCF / Net Profit
0.88×
-0.06×
TTM Free Cash FlowTrailing 4 quarters
$993.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
A
A
PACS
PACS
Q1 26
$268.0M
Q4 25
$545.0M
$-3.4M
Q3 25
$362.0M
$204.8M
Q2 25
$221.0M
$52.6M
Q1 25
$431.0M
$150.2M
Q4 24
$481.0M
$64.6M
Q3 24
$452.0M
$209.2M
Q2 24
$333.0M
$34.8M
Free Cash Flow
A
A
PACS
PACS
Q1 26
$175.0M
Q4 25
$452.0M
Q3 25
$259.0M
Q2 25
$107.0M
Q1 25
$334.0M
Q4 24
$388.0M
Q3 24
$360.0M
Q2 24
$230.0M
FCF Margin
A
A
PACS
PACS
Q1 26
9.7%
Q4 25
24.3%
Q3 25
14.9%
Q2 25
6.4%
Q1 25
19.9%
Q4 24
22.8%
Q3 24
22.8%
Q2 24
14.6%
Capex Intensity
A
A
PACS
PACS
Q1 26
5.2%
Q4 25
5.0%
Q3 25
5.9%
Q2 25
6.8%
Q1 25
5.8%
Q4 24
5.5%
Q3 24
5.8%
Q2 24
6.5%
Cash Conversion
A
A
PACS
PACS
Q1 26
0.88×
Q4 25
1.26×
-0.06×
Q3 25
1.08×
3.91×
Q2 25
1.03×
1.03×
Q1 25
1.36×
5.28×
Q4 24
1.37×
33.78×
Q3 24
1.60×
13.39×
Q2 24
1.08×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

A
A

Service Other$525.0M29%
Chemicaland Energy Market$422.0M23%
Agilent Cross Lab$273.0M15%
Environmentaland Forensics Market$177.0M10%
Food Market$166.0M9%
Academiaand Government Market$130.0M7%
Applied Markets$98.0M5%

PACS
PACS

Segment breakdown not available.

Related Comparisons